A citation-based method for searching scientific literature

Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi, Koichi Node. Cardiovasc Diabetol 2021
Times Cited: 5







List of co-cited articles
20 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Claire C J Dekkers, C David Sjöström, Peter J Greasley, Valerie Cain, David W Boulton, Hiddo J L Heerspink. Diabetes Obes Metab 2019
42
100

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Mariam Elmegaard Malik, Emil Loldrup Fosbøl,[...]. Lancet Diabetes Endocrinol 2021
40
80

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
80

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
60

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
60

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).
Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirofumi Tomiyama, Masataka Sata, Shinichiro Ueda, Jun-Ichi Oyama, Masafumi Kitakaze,[...]. ESC Heart Fail 2020
30
40

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
394
40

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Atsushi Tanaka, Teruo Inoue, Masafumi Kitakaze, Jun-Ichi Oyama, Masataka Sata, Isao Taguchi, Wataru Shimizu, Hirotaka Watada, Hirofumi Tomiyama, Junya Ako,[...]. Cardiovasc Diabetol 2016
25
40


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
40

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
379
40


Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
480
40

Prognostic Value of Estimated Plasma Volume in Heart Failure.
Kévin Duarte, Jean-Marie Monnez, Eliane Albuisson, Bertram Pitt, Faiez Zannad, Patrick Rossignol. JACC Heart Fail 2015
72
40

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
552
40

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
449
40

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
Jens Jordan, Jens Tank, Karsten Heusser, Tim Heise, Christoph Wanner, Martina Heer, Sreeraj Macha, Michaela Mattheus, Søren S Lund, Hans J Woerle,[...]. J Am Soc Hypertens 2017
43
40

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
William L Baker, Lindsay R Smyth, Daniel M Riche, Emily M Bourret, Kevin W Chamberlin, William B White. J Am Soc Hypertens 2014
287
40

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Karen M Hallow, Gabriel Helmlinger, Peter J Greasley, John J V McMurray, David W Boulton. Diabetes Obes Metab 2018
214
40

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Brendon L Neuen, Clare Arnott, Vlado Perkovic, Gemma Figtree, Dick de Zeeuw, Greg Fulcher, Min Jun, Meg J Jardine, Sophia Zoungas, Carol Pollock,[...]. Diabetes Obes Metab 2021
22
20

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Silvio E Inzucchi, David Fitchett, Dubravka Jurišić-Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T George, Bernard Zinman. Diabetes Obes Metab 2020
41
20

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Frederick A Masoudi, Silvio E Inzucchi, Yongfei Wang, Edward P Havranek, JoAnne M Foody, Harlan M Krumholz. Circulation 2005
361
20



Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.
Alessandra Dei Cas, Sadiya S Khan, Javed Butler, Robert J Mentz, Robert O Bonow, Angelo Avogaro, Diethelm Tschoepe, Wolfram Doehner, Stephen J Greene, Michele Senni,[...]. JACC Heart Fail 2015
187
20

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.
Elizabeth Selvin, Shari Bolen, Hsin-Chieh Yeh, Crystal Wiley, Lisa M Wilson, Spyridon S Marinopoulos, Leonard Feldman, Jason Vassy, Renee Wilson, Eric B Bass,[...]. Arch Intern Med 2008
221
20

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
20

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sushrima Gan, Adem Y Dawed, Louise A Donnelly, Anand T N Nair, Colin N A Palmer, Viswanathan Mohan, Ewan R Pearson. Diabetes Care 2020
24
20

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Eric J Velazquez, David A Morrow, Adam D DeVore, Carol I Duffy, Andrew P Ambrosy, Kevin McCague, Ricardo Rocha, Eugene Braunwald. N Engl J Med 2019
472
20

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
Dean T Eurich, Sumit R Majumdar, Finlay A McAlister, Ross T Tsuyuki, Jeffrey A Johnson. Diabetes Care 2005
281
20

Glycemic control and heart failure among adult patients with diabetes.
C Iribarren, A J Karter, A S Go, A Ferrara, J Y Liu, S Sidney, J V Selby. Circulation 2001
479
20


2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
20


Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.
Jacob A Udell, Matthew A Cavender, Deepak L Bhatt, Saurav Chatterjee, Michael E Farkouh, Benjamin M Scirica. Lancet Diabetes Endocrinol 2015
184
20


Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso, Katherine Esposito. Cardiovasc Diabetol 2021
15
20

Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.
Marco Dauriz, Giovanni Targher, Pier Luigi Temporelli, Donata Lucci, Lucio Gonzini, Gian Luigi Nicolosi, Roberto Marchioli, Gianni Tognoni, Roberto Latini, Franco Cosmi,[...]. J Am Heart Assoc 2017
41
20

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Mark C Petrie, Subodh Verma, Kieran F Docherty, Silvio E Inzucchi, Inder Anand, Jan Belohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer,[...]. JAMA 2020
172
20


Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.
Matthew J Crowley, Clarissa J Diamantidis, Jennifer R McDuffie, C Blake Cameron, John W Stanifer, Clare K Mock, Xianwei Wang, Shuang Tang, Avishek Nagi, Andrzej S Kosinski,[...]. Ann Intern Med 2017
137
20

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
Petar M Seferović, Mark C Petrie, Gerasimos S Filippatos, Stefan D Anker, Giuseppe Rosano, Johann Bauersachs, Walter J Paulus, Michel Komajda, Francesco Cosentino, Rudolf A de Boer,[...]. Eur J Heart Fail 2018
259
20

Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
James L Januzzi, Jialin Xu, JingWei Li, Wayne Shaw, Richard Oh, Michael Pfeifer, Javed Butler, Naveed Sattar, Kenneth W Mahaffey, Bruce Neal,[...]. J Am Coll Cardiol 2020
28
20

Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.
Walter Masson, Augusto Lavalle-Cobo, Martín Lobo, Gerardo Masson, Graciela Molinero. Eur J Prev Cardiol 2021
10
20


Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.
Wendy L Bennett, Nisa M Maruthur, Sonal Singh, Jodi B Segal, Lisa M Wilson, Ranee Chatterjee, Spyridon S Marinopoulos, Milo A Puhan, Padmini Ranasinghe, Lauren Block,[...]. Ann Intern Med 2011
392
20

Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.
Dean T Eurich, Daniala L Weir, Sumit R Majumdar, Ross T Tsuyuki, Jeffrey A Johnson, Lisa Tjosvold, Saskia E Vanderloo, Finlay A McAlister. Circ Heart Fail 2013
206
20


Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus.
Yvonne M F Chia, Tiew-Hwa K Teng, Wan T Tay, Inder Anand, Michael R MacDonald, Jonathan Yap, Chanchal Chandramouli, A Mark Richards, Jasper Tromp, Wouter Ouwerkerk,[...]. Eur J Heart Fail 2019
5
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.